[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100563352":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":52,"centralContacts":56,"locations":66,"responsibleParty":347,"collaborators":349,"id":360,"slug":361,"hasResults":362,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":35,"eligibilityCriteria":366,"healthyVolunteers":362,"sex":367,"minAge":368,"maxAge":35,"enrollmentInfo":369,"targetDuration":35,"studyType":372,"phases":373,"briefSummary":375,"conditions":376,"keywords":378,"overallStatus":69,"whyStopped":35,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":392},{"fullName":5,"class":6},"Incyte Corporation","INDUSTRY",[8,16,19,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose Finding Run-In Group 1: Tac\u002FMTX\u002FRuxolitnib Dose 1","EXPERIMENTAL","Tacrolimus\u002F methotrexate\u002F ruxolitinib (Tac\u002FMTX\u002FRux) at the protocol defined doses.",[13,14,15],"Drug: Tacrolimus (Tac)","Drug: Methotrexate (MTX)","Drug: Ruxolitinib (Rux)",{"label":17,"type":10,"description":11,"interventionNames":18},"Dose Finding Run-In Group 2: Tac\u002FMTX\u002FRuxolitnib Dose 2",[13,14,15],{"label":20,"type":10,"description":11,"interventionNames":21},"Main Study Group A: Tac\u002FMTX\u002FRuxolitnib",[13,14,15],{"label":23,"type":24,"description":25,"interventionNames":26},"Main Study Group B: PTCy\u002FTac\u002FMMF","ACTIVE_COMPARATOR","Post-transplant cyclophosphamide\u002F tacrolimus\u002F mycophenolate mofetil (PTCy\u002FTac\u002FMMF) at the protocol defined doses.",[13,27,28],"Drug: Cyclophosphamide","Drug: Mycophenolate mofetil (MMF)",[30,36,40,46,49],{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":35},"DRUG","Tacrolimus (Tac)","Tablet or intravenously (IV)",[9,17,20,23],null,{"type":31,"name":37,"description":38,"armGroupLabels":39,"otherNames":35},"Methotrexate (MTX)","Intravenously (IV)",[9,17,20],{"type":31,"name":41,"description":42,"armGroupLabels":43,"otherNames":44},"Ruxolitinib (Rux)","Tablet",[9,17,20],[45],"Jakafi, INCB018424",{"type":31,"name":47,"description":38,"armGroupLabels":48,"otherNames":35},"Cyclophosphamide",[23],{"type":31,"name":50,"description":33,"armGroupLabels":51,"otherNames":35},"Mycophenolate mofetil (MMF)",[23],[53],{"name":54,"affiliation":5,"role":55},"Incyte Medical Monitor","STUDY_DIRECTOR",[57,62],{"name":58,"role":59,"phone":60,"phoneExt":35,"email":61},"Incyte Corporation Call Center (US)","CONTACT","1.855.463.3463","medinfo@incyte.com",{"name":63,"role":59,"phone":64,"phoneExt":35,"email":65},"Incyte Corporation Call Center (ex-US)","+800 00027423","eumedinfo@incyte.com",[67,81,90,100,109,119,129,139,149,155,165,174,180,190,199,205,215,224,233,243,252,262,272,282,292,298,308,318,328,338],{"facility":68,"status":69,"city":70,"state":71,"zip":72,"country":73,"countryCode":74,"cosmosGeoPoint":75,"geoPoint":80,"contacts":35},"Stanford Cancer Center","RECRUITING","Palo Alto","California","94304","United States","US",{"type":76,"coordinates":77},"Point",[78,79],-122.14302,37.44188,{"lat":79,"lon":78},{"facility":82,"status":69,"city":83,"state":71,"zip":84,"country":73,"countryCode":74,"cosmosGeoPoint":85,"geoPoint":89,"contacts":35},"University of California San Francisco","San Francisco","94158",{"type":76,"coordinates":86},[87,88],-122.41942,37.77493,{"lat":88,"lon":87},{"facility":91,"status":69,"city":92,"state":93,"zip":94,"country":73,"countryCode":74,"cosmosGeoPoint":95,"geoPoint":99,"contacts":35},"University of Miami","Miami","Florida","33136",{"type":76,"coordinates":96},[97,98],-80.19366,25.77427,{"lat":98,"lon":97},{"facility":101,"status":69,"city":102,"state":93,"zip":103,"country":73,"countryCode":74,"cosmosGeoPoint":104,"geoPoint":108,"contacts":35},"Moffitt Cancer Center","Tampa","33612",{"type":76,"coordinates":105},[106,107],-82.45843,27.94752,{"lat":107,"lon":106},{"facility":110,"status":69,"city":111,"state":112,"zip":113,"country":73,"countryCode":74,"cosmosGeoPoint":114,"geoPoint":118,"contacts":35},"Blood and Marrow Transplant Group of Georgia","Atlanta","Georgia","30342",{"type":76,"coordinates":115},[116,117],-84.38798,33.749,{"lat":117,"lon":116},{"facility":120,"status":69,"city":121,"state":122,"zip":123,"country":73,"countryCode":74,"cosmosGeoPoint":124,"geoPoint":128,"contacts":35},"Indiana University Cancer Center","Indianapolis","Indiana","46202",{"type":76,"coordinates":125},[126,127],-86.15804,39.76838,{"lat":127,"lon":126},{"facility":130,"status":69,"city":131,"state":132,"zip":133,"country":73,"countryCode":74,"cosmosGeoPoint":134,"geoPoint":138,"contacts":35},"University of Kansas Hospital Authority","Kansas City","Kansas","66160",{"type":76,"coordinates":135},[136,137],-94.62746,39.11417,{"lat":137,"lon":136},{"facility":140,"status":69,"city":141,"state":142,"zip":143,"country":73,"countryCode":74,"cosmosGeoPoint":144,"geoPoint":148,"contacts":35},"Massachusetts General Hospital","Boston","Massachusetts","02114",{"type":76,"coordinates":145},[146,147],-71.05977,42.35843,{"lat":147,"lon":146},{"facility":150,"status":69,"city":141,"state":142,"zip":151,"country":73,"countryCode":74,"cosmosGeoPoint":152,"geoPoint":154,"contacts":35},"Dana Farber Cancer Institute","02215",{"type":76,"coordinates":153},[146,147],{"lat":147,"lon":146},{"facility":156,"status":69,"city":157,"state":158,"zip":159,"country":73,"countryCode":74,"cosmosGeoPoint":160,"geoPoint":164,"contacts":35},"University of Michigan","Ann Arbor","Michigan","48109",{"type":76,"coordinates":161},[162,163],-83.74088,42.27756,{"lat":163,"lon":162},{"facility":166,"status":69,"city":167,"state":158,"zip":168,"country":73,"countryCode":74,"cosmosGeoPoint":169,"geoPoint":173,"contacts":35},"Karmanos Cancer Institute","Detroit","48201",{"type":76,"coordinates":170},[171,172],-83.04575,42.33143,{"lat":172,"lon":171},{"facility":175,"status":69,"city":167,"state":158,"zip":176,"country":73,"countryCode":74,"cosmosGeoPoint":177,"geoPoint":179,"contacts":35},"Henry Ford Hospital","48202",{"type":76,"coordinates":178},[171,172],{"lat":172,"lon":171},{"facility":181,"status":69,"city":182,"state":183,"zip":184,"country":73,"countryCode":74,"cosmosGeoPoint":185,"geoPoint":189,"contacts":35},"Washington University","St Louis","Missouri","63110",{"type":76,"coordinates":186},[187,188],-90.19789,38.62727,{"lat":188,"lon":187},{"facility":191,"status":69,"city":192,"state":192,"zip":193,"country":73,"countryCode":74,"cosmosGeoPoint":194,"geoPoint":198,"contacts":35},"Mount Sinai Hospital","New York","10029",{"type":76,"coordinates":195},[196,197],-74.00597,40.71427,{"lat":197,"lon":196},{"facility":200,"status":69,"city":192,"state":192,"zip":201,"country":73,"countryCode":74,"cosmosGeoPoint":202,"geoPoint":204,"contacts":35},"Memorial Sloan Kettering","10065",{"type":76,"coordinates":203},[196,197],{"lat":197,"lon":196},{"facility":206,"status":69,"city":207,"state":208,"zip":209,"country":73,"countryCode":74,"cosmosGeoPoint":210,"geoPoint":214,"contacts":35},"University of North Carolina At Chapel Hill","Chapel Hill","North Carolina","27514",{"type":76,"coordinates":211},[212,213],-79.05584,35.9132,{"lat":213,"lon":212},{"facility":216,"status":69,"city":217,"state":208,"zip":218,"country":73,"countryCode":74,"cosmosGeoPoint":219,"geoPoint":223,"contacts":35},"Levine Cancer Institute","Charlotte","28204",{"type":76,"coordinates":220},[221,222],-80.84313,35.22709,{"lat":222,"lon":221},{"facility":225,"status":69,"city":226,"state":208,"zip":227,"country":73,"countryCode":74,"cosmosGeoPoint":228,"geoPoint":232,"contacts":35},"Duke University Medical Center","Durham","27705",{"type":76,"coordinates":229},[230,231],-78.89862,35.99403,{"lat":231,"lon":230},{"facility":234,"status":69,"city":235,"state":236,"zip":237,"country":73,"countryCode":74,"cosmosGeoPoint":238,"geoPoint":242,"contacts":35},"Cleveland Clinic","Cleveland","Ohio","44195",{"type":76,"coordinates":239},[240,241],-81.69541,41.4995,{"lat":241,"lon":240},{"facility":244,"status":69,"city":245,"state":236,"zip":246,"country":73,"countryCode":74,"cosmosGeoPoint":247,"geoPoint":251,"contacts":35},"Ohio State University","Columbus","43210",{"type":76,"coordinates":248},[249,250],-82.99879,39.96118,{"lat":250,"lon":249},{"facility":253,"status":69,"city":254,"state":255,"zip":256,"country":73,"countryCode":74,"cosmosGeoPoint":257,"geoPoint":261,"contacts":35},"Oregon Health & Science University","Portland","Oregon","97239",{"type":76,"coordinates":258},[259,260],-122.67621,45.52345,{"lat":260,"lon":259},{"facility":263,"status":69,"city":264,"state":265,"zip":266,"country":73,"countryCode":74,"cosmosGeoPoint":267,"geoPoint":271,"contacts":35},"University of Pennsylvania","Philadelphia","Pennsylvania","19104",{"type":76,"coordinates":268},[269,270],-75.16362,39.95238,{"lat":270,"lon":269},{"facility":273,"status":69,"city":274,"state":275,"zip":276,"country":73,"countryCode":74,"cosmosGeoPoint":277,"geoPoint":281,"contacts":35},"Medical University of South Carolina","Charleston","South Carolina","29425",{"type":76,"coordinates":278},[279,280],-79.93275,32.77632,{"lat":280,"lon":279},{"facility":283,"status":69,"city":284,"state":285,"zip":286,"country":73,"countryCode":74,"cosmosGeoPoint":287,"geoPoint":291,"contacts":35},"Sarah Cannon","Nashville","Tennessee","37203",{"type":76,"coordinates":288},[289,290],-86.78444,36.16589,{"lat":290,"lon":289},{"facility":293,"status":69,"city":284,"state":285,"zip":294,"country":73,"countryCode":74,"cosmosGeoPoint":295,"geoPoint":297,"contacts":35},"Vanderbilt Medical Center","37232",{"type":76,"coordinates":296},[289,290],{"lat":290,"lon":289},{"facility":299,"status":69,"city":300,"state":301,"zip":302,"country":73,"countryCode":74,"cosmosGeoPoint":303,"geoPoint":307,"contacts":35},"Baylor College of Medicine","Houston","Texas","77030",{"type":76,"coordinates":304},[305,306],-95.36327,29.76328,{"lat":306,"lon":305},{"facility":309,"status":69,"city":310,"state":311,"zip":312,"country":73,"countryCode":74,"cosmosGeoPoint":313,"geoPoint":317,"contacts":35},"Virginia Commonwealth University, North Hospital","Richmond","Virginia","23298",{"type":76,"coordinates":314},[315,316],-77.46026,37.55376,{"lat":316,"lon":315},{"facility":319,"status":69,"city":320,"state":321,"zip":322,"country":73,"countryCode":74,"cosmosGeoPoint":323,"geoPoint":327,"contacts":35},"Fred Hutchinson Cancer Research Center","Seattle","Washington","98109",{"type":76,"coordinates":324},[325,326],-122.33207,47.60621,{"lat":326,"lon":325},{"facility":329,"status":69,"city":330,"state":331,"zip":332,"country":73,"countryCode":74,"cosmosGeoPoint":333,"geoPoint":337,"contacts":35},"University of Wisconsin","Madison","Wisconsin","53705",{"type":76,"coordinates":334},[335,336],-89.40123,43.07305,{"lat":336,"lon":335},{"facility":339,"status":69,"city":340,"state":331,"zip":341,"country":73,"countryCode":74,"cosmosGeoPoint":342,"geoPoint":346,"contacts":35},"Medical College of Wisconsin","Milwaukee","53226",{"type":76,"coordinates":343},[344,345],-87.90647,43.0389,{"lat":345,"lon":344},{"type":348,"investigatorFullName":35,"investigatorTitle":35,"investigatorAffiliation":35,"oldNameTitle":35,"oldOrganization":35},"SPONSOR",[350,353,356,358],{"name":351,"class":352},"Blood and Marrow Transplant Clinical Trials Network","NETWORK",{"name":354,"class":355},"National Institutes of Health (NIH)","NIH",{"name":357,"class":355},"National Heart, Lung, and Blood Institute (NHLBI)",{"name":359,"class":355},"National Cancer Institute (NCI)","100563352","phase-3-a-study-of-tacrolimusmethotrexateruxolitinib-versus-post-transplant-cyclophosphamidetacrolimusmycophenolate-mofetil-in-non-myeloablativereduced-intensity-conditioning-allogeneic-peripheral-blood-stem-cell-transplantation-bmt-ctn-2203-100563352",false,"NCT06615050","A Study of Tacrolimus\u002FMethotrexate\u002FRuxolitinib Versus Post-Transplant Cyclophosphamide\u002FTacrolimus\u002FMycophenolate Mofetil in Non-Myeloablative\u002FReduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)","A Randomized, Multicenter, Phase III Trial of Tacrolimus\u002FMethotrexate\u002FRuxolitinib Versus Post-Transplant Cyclophosphamide\u002FTacrolimus\u002FMycophenolate Mofetil in Non-Myeloablative\u002FReduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation","Inclusion Criteria:\n\n* Age 18.0 years or older at the time of enrollment.\n* Participants undergoing allogeneic HCT for one of the following indications:\n\n  * Acute leukemia or chronic myelogenous leukemia with no circulating blasts and with less than 5% blasts in the bone marrow. Therapy related myeloid neoplasms are allowed.\n  * Myelodysplasia\u002Fchronic myelomonocytic leukemia with no circulating blasts and with less than 10% blasts in the bone marrow (higher blast percentage allowed in MDS due to lack of differences in outcomes with \\\u003C 5% versus 5-10% blasts in this disease). Therapy related myeloid neoplasms are allowed.\n  * Lymphoma \\[follicular lymphoma, Hodgkin lymphoma, diffuse large B cell lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma and anaplastic large cell lymphoma\\].\n* Planned NMA\u002Freduced intensity conditioning regimen.\n* Participants must have a related or unrelated PBSC donor as follows:\n\n  * Sibling donor must be a 6\u002F6 match for HLA-A and -B at intermediate (or higher) resolution, and -DRB1 at high resolution using DNA-based typing and must be willing to donate peripheral blood stem cells and meet institutional criteria for donation. HLA-matched parents and children may be used as donors.\n  * Unrelated donor must be a 7\u002F8 or 8\u002F8 match at HLA-A, -B, -C and -DRB1 at high resolution using DNA-based typing. Unrelated donor must be willing to donate peripheral blood stem cells and meet NMDP criteria for donation.\n  * Donor selection must comply with 21 CFR 1271.\n* Cardiac function: Left ventricular ejection fraction at least 45%.\n* Estimated glomerular filtration rate greater than 60 ml\u002Fmin\u002F1.73 m2 using the 2021 CKD-EPI formula Note: For eligibility, GFR by 2021 CKD-EPI is required. A baseline creatinine clearance by Cockcroft-Gault should be done to establish baseline CrCl for ruxolitinib dosing.\n* Pulmonary function: DLCO corrected for hemoglobin at least 40% and FEV1 predicted at least 50%.\n* Liver function: AST\u002FALT \\\u003C 3x ULN; Total bilirubin \\\u003C 2 mg\u002FdL excluding Gilbert's syndrome or hemolysis.\n* Karnofsky Performance Score of at least 60%.\n* Female participants (unless postmenopausal for at least one year before the screening visit, or surgically sterilized), agree to practice two effective methods of contraception at the same time, or agree to completely abstain from heterosexual intercourse, from the time of signing the informed consent through 15 months post-transplant. Fertility preservation methods will be left to institutional standards.\n* Male participants (even if surgically sterilized), of partners of women of childbearing potential must agree to one of the following: practice effective barrier contraception or abstain from heterosexual intercourse from the time of signing the informed consent through 15 months post-transplant.\n* Plans for the use of targeted small molecule inhibitor post-transplant maintenance therapy must be disclosed upon enrollment and must be used irrespective of the outcome of the randomization. Planned use of investigational maintenance agents is not permitted. Planned hypomethylating agents as maintenance therapy is not permitted.\n* Voluntary written consent obtained prior to the performance of any study-related procedure that is not a part of standard medical care, with the understanding that consent may be withdrawn by the participant at any time without prejudice to future medical care.\n\nExclusion Criteria:\n\n* Prior allogeneic transplant.\n* Active CNS involvement by malignant cells.\n* Participants with secondary AML arising from myeloproliferative neoplasms or secondary AML arising from overlap syndromes, including CMML and MDS\u002FMPN syndromes; participants with secondary AML arising from myelodysplastic neoplasm are eligible.\n* Participants with primary, post-Essential Thrombocythemia (post-ET) and post-Polycythemia Vera (post-PV) myelofibrosis.\n* Participants with uncontrolled bacterial, viral, or fungal infections (currently taking medication and with progression or no clinical improvement) at time of enrollment.\n* Active or inadequately treated latent infection with Mycobacterium tuberculosis (i.e., TB).\n* Presence of clinically significant fluid collection (ascites, pleural or pericardial effusion) that interferes with methotrexate clearance or makes methotrexate use contraindicated.\n* Participants seropositive for human immunodeficiency virus (HIV) with detectable viral load. HIV+ participants with an undetectable viral load on antiviral therapy are eligible.\n* Evidence of uncontrolled hepatitis B virus (HBV) or hepatitis C virus (HCV). The study allows:\n\n  * Positive HBV serology with undetectable viral load and ongoing antiviral prophylaxis to prevent potential HBV reactivation.\n  * Positive HCV serology with quantitative PCR for plasma HCV RNA below the lower limit of detection, with or without concurrent antiviral HCV treatment.\n* Arterial or venous thrombosis including DVT, PE, stroke, and myocardial infarction within six (6) months prior to enrollment or New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia. Catheter-associated DVT is not exclusionary.\n* Female participants who are pregnant (as per institutional practice) or lactating.\n* Participants with a serious medical or psychiatric illness likely to interfere with participation in this clinical study.\n* Participants with prior malignancies except resected non-melanoma skin cancer or treated cervical carcinoma in situ. Cancer treated with curative intent ≥ 5 years previously will be allowed. Cancer treated with curative intent \\\u003C 5 years previously must be reviewed and approved by the Protocol Officer or Chairs.\n* Planned use of ATG or alemtuzumab in conditioning regimen.\n* Planned use of prophylactic donor leukocyte infusions.\n* Prior use of ruxolitinib.\n* Prior use of immune checkpoint inhibitors (i.e., PD1, PDL1, CTLA4 modulators) within six (6) months prior to conditioning.\n* For participants with 7\u002F8 HLA-matched donors:\n\n  * Donor specific antibodies (DSAs) directed at the mismatched donor allele.\n  * Any use of desensitization protocols.\n* Treatment with any other Investigational Medicinal Product (IMP) is not allowed while on study treatment. An IMP is defined as medications without any known FDA or EMA approved indications.","ALL","18 Years",{"count":370,"type":371},572,"ESTIMATED","INTERVENTIONAL",[374],"PHASE3","The purpose of this study is to assess Tacrolimus\u002FMethotrexate\u002FRuxolitinib versus Post-Transplant Cyclophosphamide\u002FTacrolimus\u002FMycophenolate Mofetil in Non-Myeloablative\u002FReduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation",[377],"Graft-versus-host Disease (GVHD)",[377,379,380,381,382],"Chronic GvHD (cGvHD)","steroid-refractory","ruxolitinib","Janus kinase inhibitor","2026-05-19",{"date":385,"type":386},"2026-05-20","ACTUAL",{"date":388,"type":386},"2025-04-02",{"date":390,"type":371},"2031-01-17",{"name":5,"class":6},30]